



Attorney's Docket No. 35718/208677 (5718-126)

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Helentjaris *et al.* Confirmation No.: 6907  
Appl. No.: 09/780,717 Group Art Unit: 1638  
Filed: February 9, 2001 Examiner: R. Kallis  
For: NOVEL INVERTASE INHIBITORS AND METHODS OF USE

**RECEIVED**

MAR 04 2003

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

- ☐ Applicant claims small entity status. See 37 C.F.R. § 1.27.  
☐ No additional fee is required.

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
TOTAL	* 25	** 24	= 1	X9=	\$	X18=	\$ 18
INDEP	* 9	*** 6	= 3	X42=	\$	X84=	\$ 252
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				TOTAL ADD FEE \$		OR TOTAL	\$ 270


- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

- ☐ Please charge my Deposit Account No. 16-0605 in the amount of \$ .  
☒ A check in the amount \$270 to cover the additional fee is enclosed.  
☒ The Commissioner is hereby authorized to charge any deficiency in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.

In re: Helentjaris *et al.*  
Appl. No.: 09/780,717  
Filed: February 9, 2001  
Atty. Dock. No. 35718/208677 (5718-126)  
Page 2

- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.  
☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,



Andrew O. Scheinman  
Registration No. 50,730  
Attorney of Record

RECEIVED

MAR 04 2003


TECH CENTER 1600/2900


**Customer No. 29122**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

"Express Mail" Mailing Label Number EL 868643985 US  
Date of Deposit: **February 24, 2003**

I hereby certify that this paper or fee is being deposited  
with the United States Postal Service "Express Mail Post  
Office to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to:

Commissioner for Patents, Washington, DC 20231.

  
Marilyn Muñoz



#13  
Ormet B

Attorney's Docket No. 035718/208677 (5718-126)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Helentjaris *et al.* Confirmation No.: 6907  
Appl. No.: 09/780,717 Group Art Unit: 1638  
Filed: February 9, 2001 Examiner: R. Kallis  
For: NOVEL INVERTASE INHIBITORS AND METHODS OF USE

February 24, 2003

Commissioner for Patents  
Washington, DC 20231

AMENDMENT

Sir:

Responsive to the Office Action mailed October 23, 2002, Applicants respectfully request reexamination and reconsideration of the above-identified application in view of the following amendments and remarks.

The Examiner is respectfully requested to enter the following amendments.

In the Claims:

Please cancel claims 1, 14, and 15 without prejudice to or disclaimer of the subject matter contained therein.

Please amend claims 2-7, 11-13, and 20-22 to read as follows:

2. (amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- a) a nucleotide sequence set forth in SEQ ID NO:1;
- b) a nucleotide sequence that is an antisense sequence for the nucleotide sequence set forth in SEQ ID NO:1, wherein said antisense sequence hybridizes to the nucleotide sequence set forth in SEQ ID NO:1 under high stringency hybridization conditions of 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C;

02/28/2003 YPOLITE1 00000050 09780717

02 FC:1201  
03 FC:1202

252.00 OP  
18.00 OP